Invasive group A streptococcal infection

Invasive group A streptococcal infection is an invasive bacterial disease caused by Group A Streptococcus, also identified as Streptococcus pyogenes in the source material ^[1][3]. The available sources characterize it as an uncommon infection that is nonetheless serious and associated with high case-fatality rates ^[1]. The organism is described as having multiple virulence factors that underpin invasive disease, and in a subset of cases superantigen toxins contribute to streptococcal toxic shock syndrome ^[1].

The clinical course is described as rapid and potentially severe, with early recognition emphasized because deterioration may be swift ^[1]. In pregnancy-associated cases, onset was commonly preceded by flu-like illness, including high fever, upper respiratory symptoms, and gastrointestinal symptoms, followed by early shock and strong uterine contractions suggestive of placental abruption ^[3]. The reported pregnancy series also documented high maternal and fetal/infant mortality, indicating the capacity for profound systemic illness ^[3]. Invasive disease may also present as necrotizing infection, including monomicrobial necrotizing fasciitis of the extremities ^[2].

The disease has been reported as uncommon overall, but with periodic resurgences in industrialized countries since the 1980s and an estimated incidence of about 3–4 per 100,000 population in those settings ^[1]. Recent epidemiological data from England suggested increasing incidence, and one source noted that the proportion of affected children had risen ^[2]. In a review of pregnancy-associated cases, infection was reported more often in multiparous women and in the third trimester, with a seasonal concentration from winter to spring ^[3]. Source-backed detail on reservoir ecology or broader community exposure patterns beyond these observations is not yet available.

The provided sources do not give a direct route of transmission for invasive group A streptococcal infection ^[1][3][2]. They do indicate that disease arises from infection with Group A Streptococcus and that invasive capacity is linked to bacterial virulence factors, but they do not specify whether acquisition is via respiratory, contact, or other exposure pathways ^[1]. Source-backed detail on transmission persistence or environmental reservoirs is not yet available.

The sources identify infants, pregnant women, and older adults as increased-risk groups for invasive group A streptococcal infection ^[1]. A pregnancy case review further suggested susceptibility in multiparous women and in the third trimester ^[3]. One source also reported that nearly 40% of affected individuals had no predisposing illnesses or risk factors, so absence of known risk factors does not exclude severe disease ^[2].

The sources emphasize prevention through vigilance, early recognition, and rapid initiation of care for suspected cases rather than a specific public-health prevention package ^[1][2]. For pregnancy-associated invasive disease, early use of antibiotics and intravenous immunoglobulin were associated with improved outcomes in the reviewed cases, but the sources present these as management-associated findings rather than general preventive measures ^[3]. A 2024 review notes an ongoing need for a Group A Streptococcus vaccine and describes vaccine development as active but not yet resolved ^[4].

In surveillance terms, this condition should be read as a rare but high-severity invasive bacterial disease with potential for abrupt progression and substantial mortality ^[1][3]. Monitoring should pay attention to severe syndromes such as necrotizing fasciitis, streptococcal toxic shock syndrome, and pregnancy-associated fulminant illness with shock ^[2][1][3]. Because source-backed detail on standardized surveillance definitions or laboratory thresholds is not yet available, trend interpretation should remain anchored to clinically and microbiologically confirmed invasive cases ^[2][1].

1. 1 Steer AC et al. Invasive group a streptococcal disease: epidemiology, pathogenesis and management. Drugs. 2012 Jun 18. PMID: 22686614. doi: 10.2165/11634180-000000000-00000. PubMed: https://pubmed.ncbi.nlm.nih.gov/22686614/
2. 2 Invasive group A streptococcal infection. The Journal of Bone and Joint Surgery. British volume. 2010. doi: 10.1302/0301-620x.92b6.23447. DOI: https://doi.org/10.1302/0301-620x.92b6.23447
3. 3 Yamada T et al. Invasive group A streptococcal infection in pregnancy. J Infect. 2010 Jun. PMID: 20359498. doi: 10.1016/j.jinf.2010.03.011. PubMed: https://pubmed.ncbi.nlm.nih.gov/20359498/
4. 4 Di Pietro GM et al. Group A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen. Pathogens. 2024 Apr 24. PMID: 38787202. doi: 10.3390/pathogens13050350. PubMed: https://pubmed.ncbi.nlm.nih.gov/38787202/
5. 5 高危險族群肺炎鏈球菌感染之預防. 醫療品質雜誌. 2023. doi: 10.53106/199457952023071704009. DOI: https://doi.org/10.53106/199457952023071704009
6. 6 Invasive group A streptococcal infection and streptococcal toxic shock syndrome. Current Opinion in Infectious Diseases. 1991. doi: 10.1097/00001432-199110000-00006. DOI: https://doi.org/10.1097/00001432-199110000-00006

ICD-10

A49.1

ICD-11

1B50

Total cases

1K

Peak month

2025-01

Coverage

1 reporting countries · 2023-11-01 → 2026-05-01